Reticulocyte Maturation Parameters Are Reliable Early Predictors of Hematopoietic Engraftment after Allogeneic Stem Cell Transplantation  by Molina, J.R. et al.
R
E
a
I
b
w
i
i
a
i
n
a
Biology of Blood and Marrow Transplantation 13:172-182 (2007)
 2007 American Society for Blood and Marrow Transplantation
1083-8791/07/1302-0001$32.00/0
doi:10.1016/j.bbmt.2006.09.007
1eticulocyte Maturation Parameters Are Reliable
arly Predictors of Hematopoietic Engraftment
fter Allogeneic Stem Cell Transplantation
J. R. Molina, J. Sanchez-Garcia, A. Torres, M. A. Alvarez, J. Serrano, J. Casaño, P. Gomez,
F. Martinez, A. Rodriguez, C. Martin
Hematology Department and Bone Marrow Transplantation Unit, University Hospital Reina Soﬁa, Cordoba, Spain
Correspondence and reprint requests: J. Sanchez-Garcia, MD, PhD, Hematology Department, University Hospital
Reina Soﬁa, Avenida Menendez Pidal s/n, 14004 Cordoba, Spain (e-mail: joaquin.sanchez@cheerful.com).
Received July 27, 2006; accepted September 18, 2006
ABSTRACT
Early detection of donor-derived hematopoietic restoration after allogeneic stem cell transplantation (allo-
SCT) is a crucial issue in the management of heavily immunocompromised patients. The aim of this prospec-
tive study was to validate our previously defined cutoff values for reticulocyte maturation parameters as early
predictors of hematopoietic engraftment. Importantly, the effect of clinical variables in reticulocyte engraft-
ment was also sought. For this purpose, we prospectively studied 136 consecutive patients undergoing
allo-SCT from related (n  89) or unrelated (n  47) donors. High fluorescence reticulocytes (RETH),
immature reticulocyte fraction (IRF), mean fluorescence index (MFI), and mean reticulocyte volume (MRV)
were automatically measured in peripheral blood samples drawn on a daily basis. We previously defined
reticulocyte engraftment when MFI >10, RETH >3%, IRF >10%, and MRV >110 fL. Median neutrophil
engraftment was 18 days (range, 10-35 days); for reticulocyte parameters, the values were 14 days for IRF
(range, 7-45 days), 14 days for MFI (range, 7-43 days), 15 days for RETH (range, 7-43 days), and 21 days for
MRV (range, 9-74 days). These differences reached statistical significance for MFI and IRF when compared
with standard neutrophil recovery, even when analyzing siblings or unrelated donors separately. In univariate
analysis, donor-recipient ABO disparity adversely influenced erythroid engraftment (P  .04 for IRF, P  .03
for MFI), but the infusion of >2.9  106/kg of CD34 cells was associated with a shorter time to reach
erythroid engraftment (P  .02 for IRF and MFI). In Cox regression analysis, >100/L neutrophils and IRF
>10% were predictive parameters for standard neutrophil engraftment. Based on these findings, we suggest
that serial measurement of IRF or MFI should be routinely used to trace hematopoietic restoration after
allo-SCT because these preceded standard neutrophil recovery by a median of 4 days and are therefore very
useful to make clinical decisions.
© 2007 American Society for Blood and Marrow Transplantation
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tNTRODUCTION
Allogeneic stem cell transplantation (allo-SCT) has
ecome the only curative treatment for selected patients
ho have mainly neoplastic hematologic disorders. The
ncreasing use of alternative donors other than HLA-
dentical siblings and the use of cord blood units even in
dults are associated with a delayed engraftment and
ncreased graft failure rates up to 20% [1,2]. Prolonged
eutropenic periods after allo-SCT are associated with
n important risk of life-threatening infections, which t
72re the most common cause of transplant-related mor-
ality [3], and any sign of oncoming neutrophil recovery
ould be very useful in the management of these pa-
ients. Over the past few years, some biological param-
ters have been tested as early predictors of hematopoi-
tic recovery [4-6], but measurement of peripheral blood
eticulocytes has been the most attractive surrogate
arker [7]. Hematopoietic restoration after marrow ab-
ation by conditioning regimens is heralded by the ery-
hroid compartment because the most differentiated ery-
hroid cells are easily allowed to pass through the bone
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Reticulocytes and Allogeneic Transplantation 173arrow sinusoid cells. The introduction of automatic
ow cytometric methods for measuring these erythroid
ells has greatly improved the precision and accuracy of
eticulocyte counting and has currently replacedmanual-
isual counting techniques [8-10]. Flow cytometry has
lso let us to obtain reticulocyte maturation parameters
ased on reticulocyte total RNA content and volume.
he erythroid compartment cells in their maturation
rocess lose RNA and progressively shrink in volume,
nd thus the youngest reticulocytes contain larger
mounts of RNA and larger volumes, being the ﬁrst
opulation to appear in the bloodstream during hema-
opoietic recovery after allo-SCT.
We and others previously tested reticulocyte matu-
ation parameters as the earliest, easily measurable data
f marrow engraftment after autologous or allo-SCT
11-15]. In these series, highly ﬂuorescent reticulocytes
RETH), the sum of highly and medium ﬂuorescent
eticulocytes also known as immature reticulocyte frac-
ion (IRF), mean ﬂuorescence index (MFI), and mean
eticulocyte volume (MRV) have proved useful before
eutrophil engraftment within a range of 2 of 6 days.
ther calculated parameters such as time to doubling
RF [16] or the ratio of MRV to mean corpuscular
olume (MCV) [13] could precede neutrophil recovery
y even up 9 days before engraftment. However, the
idespread, routine use of these reticulocyte maturation
arameters as predictors of engraftment after allo-SCT
as been limited by the fact that none of them have been
alidated in large prospective series. Another important
rawback is the lack of well-deﬁned stringent and uni-
ormed engraftment criteria for each reticulocyte matu-
ation parameter among different studies [11-16].
In a pilot series of 30 consecutive patients undergo-
ng allo-SCT and 30 undergoing autologous SCT, we
pplied a statistical approach to stringently deﬁne cutoff
oints as markers of reticulocyte engraftment [11]. In the
resent study, we prospectively evaluated these pre-es-
ablished cutoffs as early predictors of hematopoietic
ecovery but with a focus on allo-SCT procedures,
hich are associated with longer neutropenia periods
nd a higher incidence of graft failure compared with
utologous transplantations. In this large consecutive
eries of allo-SCT, we include patients who received
rafts from HLA-identical sibling donors and from un-
elated and mismatched donors. We also analyzed sev-
ral clinical variables that could have inﬂuenced red cell
ngraftment and their behavior in cases of graft failure.
ETHODS
atients
Patients (n  136) who underwent allo-SCT at
he University Hospital Reina Soﬁa (Cordoba, Spain)
etween January 2000 and May 2005 were included in
his study. Clinical data are summarized in Table 1. cllo-SCTs were performed from related (n  89) or
nrelated (n  47) donors who were serologically or
llele tested for HLA-A, -B, and -C and were allele
ested speciﬁcally for HLA-DRB1 and DQB1. Nine-
een patients received grafts from donors with 1 or 2
inor disparities (5 from sibling donors and 14 from
nrelated donors) and 1 patient from a haploidentical
ibling donor. Eight patients received a nonmyeloab-
ative conditioning regimen because of age or associ-
ted comorbidity. Stem cell source was bone marrow
n  113), mobilized peripheral blood (n  14), or
ord blood (n  9). Prophylaxis against graft-versus-
ost disease (GVHD) for patients undergoing my-
loablative allo-SCT consisted mainly of a short
able 1. Clinical Characteristics of 136 Patients with Allogeneic SCT
Parameters Number %
umber of total patients 136
ge (y) at SCT, median (range) 33 (1-64)
ale/female 81/55 59.5/40.5
iagnoses
Acute leukemia 68 50
Chronic myeloid leukemia 30 22
Multiple myeloma 12 8.8
Marrow aplasia 11 8.1
Non-Hodgkin lymphoma 7 5.2
Other 8 5.9
onor type
Sibling donor* 88 64.7
Unmatched donor† 47 34.5
Haploidentical related‡ 1 0.7
BO compatibility
Compatible 87 64
Minor incompatibility 21 15.4
Major incompatibility 28 20.6
raft source
Bone marrow 113 83
Peripheral blood 14 10.3
Umbilical cord 9 6.6
reparative regimen
Myeloablative with TBI 94 69.1
Myeloablative without TBI 23 17
Nonmyeloablative 8 5.9
CY  ATG 11 8
VHD prophylaxis
CsA  MTX 118 87
MMF  CsA 8 5.9
CsA  PDR 9 6.6
ean CD34 infused cells (106/kg) 2.9
ean mononuclear infused cells (108/kg) 2.6
CT indicates stem cell transplantation; TBI, total body irradiation
(13 Gy); CY, cyclophosphamide (120 mg/kg); ATG, antithymo-
cyte globulin; PDR, prednisone; CsA, cyclosporine (3 mg/kg);
MTX, methotrexate (10 mg/m2); GVHD, graft-versus-host dis-
ease; MMF, mycophenolate mofetil (30 mg/kg).
Five sibling donors were mismatched by 1 or 2 antigens.
Fourteen unrelated donors were mismatched by 1 or 2 antigens
including all 9 umbilical cord units.
Patient grafted from haploidentical sibling donor was conditioned
with TBI, ﬂudarabine, and tiothepa and received puriﬁed pe-
ripheral blood CD34 cells without further GVHD prophylaxis.ourse of methotrexate (MTX) at a dose of 10 mg/m2
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J. R. Molina et al.174n days1,3,6, and11 plus cyclosporine (CsA)
t a dose of 1.5 mg/kg intravenously or 6.25 mg/kg
rally every 12 hours on days1 to90 that was then
apered until day 180. Prophylaxis against GVHD
or patients undergoing nonmyeloablative allo-SCT
onsisted of mycophenolate mofetil (MMF) at a dose
f 15 mg/kg orally every 12 hours from day 0 to day 40
ith subsequent tapering until day 90 and CsA at a
ose of 1.5 mg/kg intravenously or 6.25 mg/kg orally
very 12 hours on days 1 to 90 and then tapered
ntil day 180. All patients received granulocyte-
olony stimulating factor at a dose of 5 g/kg daily,
tarting 7 days after graft infusion until they achieved
or 3 consecutive days a granulocyte peripheral blood
ount 500/L. All patients received packed red
lood cell transfusions to maintain hemoglobin con-
entrations 8 g/dl (25% hematocrit) and packed
andom or single-donor platelets were transfused
hen platelet counts decreased to 20  109/L. One
undred twenty-seven patients received prophylaxis
ith 500 mg/m2 acyclovir intravenously during the
eutropenia period. All received antifungal and anti-
iotic prophylaxis (with ﬂuconazole or voriconazole
nd oﬂoxacin, respectively) since the ﬁrst day of the
onditioning regimen. No patient received erythro-
oietin during the transplantation course. During the
tudy period, no clinical interventions were taken
ased on reticulocyte maturation parameters.
ethods
Reticulocyte analysis was performed with the ABX
ENTRA 120 Retic (Horiba-ABX, Montpellier,
rance). Brieﬂy, reticulocyte counting requires a pre-
iminary manual mixing 0.8 L of whole peripheral
lood with ethylenediaminetetraacetic acid with 2.5
L of a proprietary formulation of nucleic acid of
uorochrome thiazole orange. After 25 seconds of
ncubation at 35°C, an aliquot of dilution was trans-
erred to the optical bench, and cells were analyzed
equentially to determine the true MRV by aperture
f impedance (resistivity) and ﬂuoro-ﬂow cytometry
RNA content) using a 20-mW argon ion laser light
ource. Using customized gating for each sample, re-
iculocytes are separated from mature red blood cells,
hite blood cells, and platelets. The results are dis-
layed on a reticulocyte matrix with RNA content on
he y axis and cell volume on the x axis. For each
eripheral blood sample, the analyzer obtains reticulo-
yte percentage and absolute reticulocyte count. More-
ver, because the amount of light absorbed by reticulo-
ytes is proportional to the intensity of staining and
NA content, reticulocytes are subdivided into 3 popu-
ations with low, medium, and high RNA content. With
his subdivision we obtained reticulocytes in 3 sections:
ow RNA content, medium RNA content (RETM) and
igh RNA content (RETH). The immature reticulocyte draction is a parameter calculated with the sum of
ETM plus RETH. The other 2 parameters, MFI and
RV, were calculated directly by the analyzer.
All values were determined from peripheral blood
amples drawn the day before the conditioning regi-
en, the infusion day (designated day 0), and there-
fter on a daily basis until neutrophil counts remained
500/L for 3 days. All samples were run in dupli-
ate and results are presented as mean values. Engraft-
ent was deﬁned as an absolute neutrophil count
ANC) of 500/L for 3 consecutive days and a platelet
ount of 20  109/L in peripheral blood and indepen-
ent of red blood cell transfusion.
tatistical Analysis
Results are expressed as mean  standard devia-
ion and range for reticulocyte values and median for
ngraftment days. Highly and medium ﬂuorescent re-
iculocytes are expressed as percentages, MFI as ﬂuo-
escence units, and MRV in femtoliters. We proposed
statistical model indicating erythroid engraftment
eﬁned by each reticulocyte variable: the ﬁrst post-
ransplantation day when MFI values reach 10, IRF
alues reach 10%, RETH values reach 3%, and
RV values reach 110 fL for each patient for 3
onsecutive days [11]. These cutoffs were assigned
onsidering the adjusted 25% quartile for each param-
ter on the day that myeloid engraftment occurred
ased on our previous data. These were compared
ith ANCs 100/L and 500/L (the ﬁrst day
hese peripheral blood counts were achieved).
Temporal series Kaplan-Meier and log-rank tests
ere used to compare days of engraftment for reticu-
ocyte parameters with days of ANC engraftment.
he relation between different reticulocyte parame-
ers and myeloid engraftment was estimated by simple
inear regression and correlation analysis. The effect
f clinical variables that could inﬂuence erythroid en-
raftment was examined by univariate and multivari-
te analyses using Cox regression models. P  .05 was
ccepted as statistically signiﬁcant.
ESULTS
In our consecutive series of 136 patients undergo-
ng allo-SCT, we observed 5 (3.7%) cases of primary
raft failure and 5 patients died during the neutrope-
ia period without hematopoietic recovery. The re-
aining 126 patients (92.6%) fulﬁlled engraftment
riteria with donor-derived hematopoiesis as assessed
y molecular chimerism analyses. Eight patients who
nderwent allo-SCT with nonmyeloablative condi-
ioning regimen showed a transient mixed chimerism
ith 2.4% (range, 1.1%-5.7%) of recipients’ marrow
ucleated cells measured at day 17 (range, 14-20
ays). After the conditioning regimen, absolute reticu-
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Reticulocytes and Allogeneic Transplantation 175ocyte counts decreased progressively from 115 
09/L to a nadir of 6.1  109/L on median day 9.
hereafter, increasing numbers of reticulocytes and
ncreasing percentages of immature fractions were ob-
erved throughout the recovery period.
inetics of Reticulocyte Maturation Parameters
nd Neutrophil Recovery after Allo-SCT
After the reticulocytopenia period, there was a
igniﬁcant increase in peripheral blood immature re-
iculocytes before neutrophil recovery. Median days
re listed in Table 2. Thus, using our pre-established
riteria, median engraftment days were 14 (range,
-45) for IRF,14 (range, 7-43) for MFI,15 (range,
-43) for RETH, and 21 (range, 9-74) for MRV.
yeloid engraftment (ANCs 100/L and 500/
L) occurred later than IRF and MFI (day 15
range, 9-37] and day 18 [range, 10-35], respec-
ively). These differences reached a statistical differ-
nce for IRF 10% and MFI 10 compared with an
NC 500/L (P  .01 in both cases) and for MFI
10 compared with an ANC 100/L (P  .06).
emarkably, only 2 patients did not achieve these
utoff values (1 eventually developed secondary graft
ailure), which can, therefore, be applied to 98.4% of
ases. In this large series, neither RETH 3% nor
RV 110 fL reached statistical differences com-
ared with standard neutrophil recovery. Further,
0.3% (n 13) and 44.4% (n 56) of patients did not
each cutoff values for RETH and MRV, respectively.
herefore, the most powerful predictors were IRF
nd subsequently MFI, which encompasses the ﬂuo-
escence mostly provided by high and medium ﬂuo-
escent reticulocytes.
When we considered patients with allo-SCT graft-
ng from a sibling donor (n  87), MFI reached 10 at
ay 14 (range, 7-28), whereas ANC 100/L and
500/L occurred signiﬁcantly later (P  .04 and P 
01, respectively). Likewise, IRF 10% was reached at
ay 14 (range, 7-26), which was signiﬁcantly sooner
han an ANC 500/L (P  .01). More interestingly,
atients undergoing allo-SCT from unrelated donors (n
able 2. Median (Range) Number of Days to Reach Reticulocyte Matu
ngraftment in 126 Patients with Successful Donor-Derived Hematopoi
Patients (n) IRF-DT* MFI >10 IRF >10% AM
ll (126) 11 (4-25) 14 (7-43) 14 (7-45) 1
D (87) 11 (4-23) 14 (7-28) 14 (7-26) 1
RD (39) 13 (8-25) 14 (8-43) 14 (8-45) 1
M (106) 11 (4-23) 14 (7-28) 14 (7-26) 1
CB (8) 15 (9-25) 22 (14-43) 22 (14-45) 1
PB (12) 10 (7-13) 10 (8-29) 10 (8-29) 1
CT indicates stem cell transplantation; SD, sibling donor; UR
MPB, mobilized peripheral blood; IRF-DT, immature reticuloc
reticulocyte fraction; AMC, absolute monocyte count; ANC, ab
This parameter could be applied in only approximately 50% of ca39) also achieved MFI values 10 and IRF values i10% before standard neutrophil recovery with an
NC 500/L (P  .02 and .05 for MFI and IRF,
espectively). Kaplan-Meier curves comparing reticulo-
yte maturation engraftment with ANC engraftment for
he global series and according to donor type are dis-
layed in Figures 1 and 2.
We tested all parameters that could potentially
redict an eventual hematopoietic restoration in all
onsecutive 136 patients. In Cox regression analysis,
nly 2 parameters were absolutely predictive of my-
loid engraftment: ANC 100/L and IRF 10%.
otwithstanding, it is important to highlight that an
RF 10% occurred 1-4 days sooner than an ANC
100/L in most instances.
In an autologous transplantation setting, it has
een stated that other calculated parameters, ie, the
RF doubling time (IRF-D), as the ﬁrst of 2 consec-
tive days on which the IRF value doubled from the
adir, can precede an ANC 100/L by several days
efore. In our series of allo-SCT, this parameter could
ot be stringently applied because in 59 patients
47.2%) the nadir value of IRF was virtually 0. For the
emaining 67 patients, IRF-D occurred signiﬁcantly
ooner than an ANC 100/L (P  .01).
An absolute monocyte count (AMC) 100/L
as also tested as an early predictor of eventual he-
atopoietic restoration. This cutoff value was reached
n most patients (95.2%). Median day of an AMC
100/L occurred signiﬁcantly sooner than the stan-
ard ANC 500/L (P  .02, log-rank test), but no
tatistical difference was found when compared with
n ANC 100/L (P  .3). Importantly, median days
f MFI values 10 and IRF values 10% occurred
igniﬁcantly sooner than an AMC100/L (P .009
nd .034, log-rank test, for MFI and IRF, respec-
ively). Median days are presented for all early predic-
or parameters in Table 2.
nalysis of Clinical Factors Influencing
eticulocyte Engraftment
We identiﬁed IRF and MFI as statistically signif-
arameter Engraftment, Monocyte and Standard Neutrophil
toration after Allogeneic SCT
/L ANC >100/L ANC >500/L ANC >1000/L
) 15 (9-37) 18 (10-35) 19.5 (10-35)
) 15 (9-25) 17 (10-26) 19 (10-27)
) 16 (9-37) 19 (12-48) 21 (13-35)
) 15 (9.25) 18 (12-26) 20 (13-27)
) 22 (13-37) 26 (17-48) 27 (19-35)
) 14 (10-21) 15.5 (10-22) 16.5 (10-26)
related donor; BM, bone marrow; UCB, umbilical cord blood;
tion doubling time; MFI, mean ﬂuorescence index; IRF, immature
neutrophil count.ration P
etic Res
C >100
5 (7-27
5 (9-27
5 (7-27
5 (9-25
6 (7-27
6 (7-13
D, un
yte frac
solutecant early predictors of hematopoietic recovery when
Figure 1. Kaplan-Meier curves comparing reticulocyte engraftment days and standard absolute neutrophil count (ANC) engraftment (500/L) after allogeneic transplantation. Days after transplantation are presented
on the x axis and cumulative frequency of achieving engraftment is presented on the y axis; solid lines represent reticulocyte maturation parameters for engraftment and dashed lines represent standard ANC engraftment.
Immature reticulocyte engraftment (IRF; 10%) is compared with ANC in (A) all patients with successful engraftment, (B) patients who received grafts from a sibling donor, and (C) patients who received grafts from
an unrelated donor. Mean ﬂuorescence index (MFI;10) is compared with ANC in (D) all patients with successful engraftment, (E) patients who received grafts from a sibling donor, and (F) patients who received grafts
from an unrelated donor.
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Reticulocytes and Allogeneic Transplantation 177ompared with an ANC 500/L in patients who
eceived grafts from a sibling donor or those who
eceived grafts from an unrelated donor. We also
ought other clinical factors that could inﬂuence re-
iculocyte engraftment.
As expected, reticulocyte engraftment and neutro-
hil recovery were heavily inﬂuenced by stem cell
ource (P  .01, Kruskal-Wallis test for MFI, IRF,
nd ANC). Median engraftment days are listed in
able 2, and the earliest are recorded for the mobi-
ized peripheral blood group and the latest for the
CB group. In either case, IRF and MFI precede an
NC 500/L by a minimum of 4 days, differences
hat retained statistical signiﬁcance for the bone mar-
ow grafted group (Figures 3 and 4). Therefore, IRF
nd MFI can be used to predict oncoming hemato-
oietic recovery after allo-SCT regardless of stem cell
ource.
The presence of minor ABO disparity had no
ffect on reticulocyte engraftment, but the presence of
ajor ABO disparity was an adverse factor that sig-
iﬁcantly delayed red cell engraftment as measured by
eticulocyte maturation parameters. Thus, the median
ay to reach an IRF 10% and an MFI 10 for
atients with major ABO disparity was 15 (range,
-45) and that for ABO-compatible patients was 14
range, 7-26; P  .049 and .032 for IRF and MFI,
espectively). The group of major ABO-compatible
atients with successful engraftment (n 24) included
patients grafted with umbilical cord blood (UCB)
nd 11 patients from unrelated donors. Even in this
ubset of patients, median engraftment days for MFI
igure 2. Kaplan-Meier curves comparing mean ﬂuorescence inde
ount (ANC) engraftment day (100/L) after allogeneic transplant
requency of achieving engraftment is presented on the y axis; so
chieving an ANC 100/L. (A) All patients with successful engrand IRF preceded by 2.5 days the median engraftment lay for an ANC 500/L (17.5; range, 7-48), al-
hough without reaching statistical signiﬁcance.
The number of infused CD34 cells had statistical
igniﬁcance in engraftment, which occurred sooner if
nfusion of CD34 cells was 2.9  106/kg (P  .02
or IRF and MFI). This parameter also inﬂuenced
tandard neutrophil engraftment and thus an ANC
500/L was reached signiﬁcantly sooner in patients
nfused with 2.9  106/kg.
Other clinical variables such as conditioning reg-
men, status of disease at transplantation, number of
ed cell transfusions, acute GVHD of any grade, her-
es infectious disease, and days of fever after allo-SCT
ad no statistical inﬂuence on reticulocyte engraft-
ent. The use of a short course of methotrexate as
art of acute GVHD prophylaxis did not result in a
elayed reticulocyte engraftment as measured by MFI
nd IRF values 10 (P  .33 and .44).
Table 3 presents results of univariate analysis. In
ox regression multivariate analysis, none of the
linical variables studied remained statistically sig-
iﬁcant for reticulocyte engraftment as measured by
FI or IRF.
eticulocyte Maturation Parameters in Graft
ailure Cases
When we studied 126 patients who had achieved a
uccessful donor-derived hematopoietic restoration,
n ANC 500/L was reached at day 26 in 96% of
ases. Remarkably, an MFI 10 was reached at day
23 in 96.5% of cases. Therefore, patients who did
ot achieve an MFI value 10 at day 23 were very
) engraftment (10) days and more stringent absolute neutrophil
ays after transplantation are presented on the x axis and cumulative
es represent MFI engraftment and dashed lines represent day of
and (B) patients who received grafts from a sibling donor.x (MFI
ation. D
lid linikely to develop engraftment failure. When consider-
Figure 3. Kaplan-Meier curves comparing reticulocyte engraftment days and standard absolute neutrophil count (ANC) engraftment (500/L) after allogeneic transplantation according to stem cell
source. Days after transplantation are presented on the x axis and cumulative frequency of achieving engraftment is presented on the y axis; solid lines represent reticulocyte maturation parameter
engraftment and dashed lines represent standard ANC engraftment. (A-C) Immature reticulocyte engraftment (10%) and (D-F) mean ﬂuorescence index (10) values are presented for (A, D) bone
marrow, (B, E) mobilized peripheral blood, and (C, F) umbilical cord blood.
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Reticulocytes and Allogeneic Transplantation 179ng bone marrow as the stem cell source, most patients
96.2%) reached an MFI value 10 at day 21, but
his value was reached sooner (day 19) for mobilized
eripheral blood and later for UCB (day 33).
In this series, we observed 8 cases of engraftment
ailure (5.8%). Five patients developed primary graft
ailure and 3 patients did so after transient successful
eutrophil engraftment. Clinical data of these patients
re presented in Table 4. All cases of primary graft
ailure showed no data of reticulocyte engraftment. In
of 3 patients with secondary graft failure, neither
FI nor IRF values reached 10 after allo-SCT. Six
atients received rescue stem cell infusion (5 from
llogeneic donors), with complete hematopoietic res-
oration in 2 cases.
The ﬁrst such case concerned a 42-year-old man
igure 4. Kinetic immature reticulocyte engraftment measurement
arrow, (B) mobilized peripheral blood, or (C) umbilical cord blood
ean  SE immature reticulocyte engraftment percentages is pres
able 3. Results of Univariate Analysis to Study the Effect of Clinical
ariables in Reticulocyte and Neutrophil Engraftment
Clinical Variable
P
MFI IRF ANC
onor type 0.06 0.05 0.02
tem cell source* 0.002 0.001 0.000
BO compatibility† 0.032 0.049 0.152
D34 cells infused‡ 0.026 0.022 0.008
cute GVHD 0.111 0.113 0.342
T in conditioning regimen 0.621 0.587 0.352
FI indicates mean ﬂuorescence index; IRF, immature reticulocyte
fraction; ANC, absolute neutrophil count; RT, radiotherapy;
GVHD, graft-versus-host disease.
Kruskall-Wallis test.
Patients with major ABO incompatibility versus those with ABO
compatibility.
uVersus 2.9  106/kg.ho underwent allogeneic marrow transplantation
rom an HLA-matched unrelated donor for chronic
yelogenous leukemia. He was infused with 2.5 106
D34 cells/kg and presented a modest increase in
eticulocyte parameters on day 14 without reaching
utoff values, and neutrophil counts reached up to
.23  109/L. Subsequently, there were progressive
ecreases in reticulocyte parameters and neutrophil
ounts. An autologous peripheral stem cell backup
raft, containing 1.37  107 mononuclear cells/kg,
as infused on day 36 with hematopoietic recovery
nd complete resolution of the febrile episode.
The second case concerned a 16-month-old infant
iagnosed with acute lymphoblastic leukemia. She un-
erwent allogeneic bone marrow transplantation from
HLA-identical unrelated donor and was infused with
.4  106 CD34 cells/kg. On day 18 MFI and IRF
eached their cutoff values, whereas neutrophils in-
reased to 0.5  109/L on day 23. Two days later
25) reticulocyte maturation parameters and neutro-
hil peripheral blood counts progressively decreased.
n day 49, she received a second stem cell infusion
3.15  106 CD34 cells/kg) from the same donor
fter administration of antithymocyte globulin, with
ustained erythroid and myeloid recoveries on day
21 after the second infusion.
ISCUSSION
In this study, with a large series of consecutive
atients, we have validated our previously deﬁned cut-
ff values of 10 for MFI and 10% for IRF as
logeneic stem cell transplantation for patients grafted with (A) bone
before and after stem cell infusion are presented on the x axis, and
n the y axis.after al
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J. R. Molina et al.180ived hematopoietic restoration after allo-SCT. Thus,
e can ensure in the vast majority of patients that the
NC will reach 500/L within a median of 4 days in
dvance when using our predeﬁned cutoff values for
FI and IRF. More importantly, this ﬁnding can be
pplied regardless of donor type and stem cell source.
n addition, we have also demonstrated that MFI and
RF engraftment occurred signiﬁcantly sooner than an
NC 100/L in patients who received grafts from a
ibling donor.
One major obstacle to the widespread use of re-
iculocyte maturation parameters in the stem cell
ransplantation setting has been the lack of uniform
riteria to deﬁne reticulocyte engraftment. Absolute
alue of RETH applied in previous studies [14,17] has
een progressively replaced with ﬁxed values of IRF
nd MFI or calculated by increasing doubling from
adir values [16-20]. In our pilot series, we used strin-
ent statistical criteria to establish cutoff values for
RV, RETH, MFI, and IRF in a series of 30 alloge-
eic patients and 30 autologous patients [11]. How-
ver, in the present series of allo-SCT, RETH and
RV lacked statistical signiﬁcance and nearly 40%-
0% of patients did not reach the pre-established
riteria (RETH 5% and MRV 110 fL). This ﬁnd-
ng reinforces the idea that global measurement of
uorescence as MFI or combined measurement of
ETH and RETM (IRF) results in a better and more
eliable quantiﬁcation of immature reticulocytes. As
onsequence of results observed in this study, we sug-
est that an IRF value 10% could be the standard
riterion of reticulocyte engraftment, because in the
ultivariate analysis this was the best predictor of
ventual myeloid engraftment. In addition, this ﬁxed
RF value of 10% could apply to all patients includ-
ng autologous and allogeneic transplant recipients,
an be widely and homogeneously applied to design
rospective trials, and is measurable in a reproducible
ashion in a large number of automated counters.
urrently, available automated methods to measure
eticulocytes are based on ﬂuorescence, light scatter-
ng, or absorbance. It has been demonstrated that
able 4. Clinical Data of 8 Patients Who Developed Graft Failure aft
Age Diagnose Donor Type
Stem Cell
Source
CD34  1
Infuse
42 CML UR BM 2.5
45 CML Sibling BM 1.63
34 ALL UR BM 2.20
12 Fanconi UR MPB 1.85
21 ALL UR mismatch UCB 0.10
33 CML UR BM 1.58
1 ALL UR BM 3.4
29 ALL UR MPB 4.66
CT indicates stem cell transplantation; CML, chronic myeloid
BM, bone marrow; MPB, mobilized peripheral blood; UCB, umuorescence-based methods, regardless of the type of Iucleic acid used (thiazole orange, auramine O,
D4K530), have a very good linear correlation
21,22]. In addition, the application of doubling nadir
alues, although it is somehow arbitrary in patients
ith IRF values of 0 during the pancytopenic period
nearly 50% of cases in our experience), might be a
ood practice because successive increases from 0 or
he nadir could point out a prompt reticulocyte recov-
ry.
As expected, several factors inﬂuenced reticulocyte
ngraftment and standard neutrophil engraftment. In
his sense, use of alternative donors, UCB as a stem
ell source, and low doses of CD34 cells are associated
ith a signiﬁcant delay in myeloid and erythroid en-
raftments. Nevertheless, we have demonstrated that
n these instances an IRF 10% and an MFI 10
recede neutrophil engraftment. Our major concern
as the effect of ABO disparity that could selectively
mpair reticulocyte engraftment and limit clinical use.
inor ABO disparity did not result in a signiﬁcant
elay when compared with ABO-compatible allo-
CT procedures but, as expected, major ABO dispar-
ty resulted in a signiﬁcant delayed reticulocyte en-
raftment. However, IRF and MFI still precede
eutrophil recovery, although by only 2.5 days instead
f 4 days observed in the entire series.
Measurement of IRF and MFI or IRF-D as har-
ingers of oncoming neutrophil recovery is likely to
dd useful information on patient management mainly
n 2 aspects: management of febrile neutropenia and
rimary graft failure. Current guidelines for the use of
ntimicrobial agents in neutropenic patients have ad-
ocated identifying low-risk patients who can be con-
ervatively managed or high-risk patients who must
ndergo intensive diagnostic and therapeutic mea-
ures [23]. Expected resolution of neutropenia in 10
ays and early evidence of bone marrow recovery are
pivotal factors for the low-risk assignment and both
an only be accurately assessed with daily IRF deter-
inations. Neutropenic patients with fever lasting 5
ays after allo-SCT with IRF values10% and lack of
eneic SCT
Graft Failure
Stem Cell
Rescue Day of Infusion Outcome
Primary Auto 36 Alive
Primary Allo 44 Death
Primary Allo 40 Death
Primary NA NA Death
Primary NA NA Death
Secondary Allo 60 Death
Secondary Allo 49 Alive
Secondary Allo 42 Death
ia; ALL, acute lymphoblastic leukemia; UR, unrelated donor;
cord blood; NA, not applicable; Auto, autologous; Allo, allogeneic.er Allog
06/kg
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leukemRF-D are likely to still have prolonged neutropenia
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Reticulocytes and Allogeneic Transplantation 181nd therefore are at a high risk of life-threatening
nvasive fungal infections. Thus, if clinically indicated,
hey might be considered candidates to receive addi-
ional treatment options such as granulocyte transfu-
ions or to be enrolled in clinical trials of novel anti-
ungal agents with activity against ﬁlamentous fungi
24,25]. In addition, in agreement with Grazziutti et al
16], we suggest that IRF measurement could homo-
eneously identify high-risk patients enrolled in clin-
cal trials with antimicrobial drugs for febrile neutro-
enia, thus avoiding the confounding factor of the
eneﬁcial effect of resolving neutropenia.
Conversely, serial measurement of IRF after allo-
CT might provide very useful information when
rimary graft failure is suspected. The usefulness in
econdary graft failure could not be assessed in this
tudy, because reticulocyte maturation parameters
ere prospectively collected until standard neutrophil
ecovery. Primary graft failure after allo-SCT is asso-
iated with considerable morbidity and mortality re-
ated to infections and hemorrhagic complications. In
ost instances, an autologous stem cell backup is not
vailable and the greatest chance of trilineage recovery
ith the lowest risk of GVHD seems to be accom-
lished with a boost of donor CD34 selected periph-
ral blood cells [26]. It is not clear how long to wait
efore rearranging a second donation, which can take
n additional 1-4 weeks. Thus, as a consequence of the
esults of our study, we already know that 95% of
atients who receive grafts from an HLA-matched
onor or using bone marrow as the stem cell source
hould achieve an IRF 10% and an MFI 10 at day
21. Patients who received grafts from a mismatched
onor, excluding those cases using UCB, should also
chieve those values at day 25. Therefore, with the
nowledge that 5% of patients will eventually dem-
nstrate engraftment, we suggest early planning of
tem cell rescue at those deadlines (autologous or
llogeneic, according to availability) to prevent a fatal
utcome. Prospective studies are needed to assess the
ontribution of the IRF measurement to the clinical
anagement of patients after allo-SCT.
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